Drug Profile
Research programme: disruptors of Pseudomonas biofilms - Antabio
Alternative Names: DPB - AntabioLatest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Antabio
- Class Antibacterials; Small molecules
- Mechanism of Action Cell physiology modulators; Pseudolysin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pseudomonal infections
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for research development in Pseudomonal-infections(Adjunctive treatment) in USA (Inhalation)
- 06 Jan 2020 Research programme: disruptors of Pseudomonas biofilms - Antabio is still in Early Research phase for Cystic fibrosis in USA (Antabio Pipeline,
- 28 Nov 2019 No recent reports of development identified for research development in Pseudomonal-infections(Adjunctive treatment) in USA (Inhalation)